Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition Fanconi Anemia (FA) is a rare recessive syndrome characterized by cellular hypersensitivity to DNA-cross-linking agents. To date, 13 FA complementation groups have been described and all 13 genes associated to each of these groups have been currently identified. Three of the known FA genes are also high-risk (FANCD1/ BRCA2) or moderate-risk (FANCN/PALB2 and FANCJ/BRIP1) breast cancer susceptibility genes, which makes all members of the FA pathway particularly attractive breast cancer candidate genes. Most FA genes have been screened for mutations in breast cancer families negative for BRCA1/2 mutations but the role of FANCL, FANCM and the recently identified FANCI has not been evaluated to date. This fact and novel data sustaining greater functional relevance of the three genes within the FA pathway prompted us to scrutinize all coding sequences and splicing sites of FANCI, FANCL and FANCM in 95 BRCA1/2-negative index cases from Spanish high-risk breast cancer families. We identified 68 sequence variants of which 24 were coding and 44 non-coding. Six exonic and 26 non-coding variants had not been described previously. None of the coding changes caused clearly pathogenic changes and computational analysis of all non-described intronic variants did not revealed major impact in splicing. With the present study, all known FA genes have been evaluated within the context of breast cancer high-risk predisposition. Our results rule out a major role of FANCI, FANCL and FANCM in familial breast cancer susceptibility, suggesting that among the 13 known FA genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
Introduction
Fanconi Anemia (FA) is a rare recessive genetic disorder characterized by progressive bone marrow failure, developmental abnormalities and high incidence of cancer including leukemias and solid tumors (1, 2) . There are at least 13 FA complementation groups (A, B, C, D1, D2, E, F, G, I, J, L, M and N) and all 13 genes associated to each of these groups have been currently identified. FANCI is the last discovered FA gene, not being assigned to its complementation group until recently in 2007 (3) (4) (5) . FA proteins participate as signal transducers and DNA processors in a common DNA damage response pathway (the FA-BRCA network) involved in the repair of DNA interstrand cross-links (6) .
Eight FA proteins (FANCA, B, C, E, F, G, L and M) form the upstream FA complex or 'FA core complex' that in response to DNA damage activates a second group of proteins, the 'FA ID Complex' (FANCD2 and FANCI) through monoubiquitination. Ubiquitinated-ID complex subsequently translocates to sites of DNA damage where it interacts with the 'downstream FA proteins' (FANCD1/ BRCA2, FANCN/PALB2 and FANCJ/BRIP1) as well as with other key DNA repair proteins. The exact mechanism of the repair reaction is not fully understood but it has been proposed that a complex crosstalk between the FA proteins and other DNA repair molecules belonging to the nucleotide excision repair, homologous recombination and translesion synthesis pathways would be required in order to remove the interstrand cross-links at stalled replication forks (6, 7) .
The discovery in 2002 that FANCD1 was BRCA2 was the defining moment in which attention was drawn to the so far unknown link between FA and breast cancer susceptibility (8) . This finding made reasonable to hypothesize that other FA proteins might be involved in breast cancer risk. Most of the FA core complex genes were subsequently screened for mutations in familial breast cancer patients negative for mutations in the BRCA genes but pathogenic changes were not found (9) . However, recent studies have revealed that FANCJ/BRIP1 and FANCN/PALB2 are moderate-risk breast cancer genes (10, 11) . These exciting results launched a whole series of further analysis of both genes. In the case of PALB2, additional data confirmed an implication of the gene in $1% of hereditary breast cancer not due to BRCA1/2 mutations (12,13), demonstrated greater incidence within specific ethnic backgrounds presenting PALB2 founder mutations (14, 15) or defined higher penetrance estimations for specific PALB2 mutations (13, 16) .
In the recent years, we have gained new insights on the striking connection between FA and breast cancer as mounting evidence indicates that the 'FA pathway' form part of a wider DNA damage response network that includes the BRCA genes and that has been termed the 'FA-BRCA pathway' (6, 17) . Despite these encouraging results, there are FA genes whose potential implication in breast cancer risk has not yet been tested. We could recently ruled out a major involvement of the core complex-FA protein FANCB in breast cancer predisposition (12) but the contribution of FANCL, FANCM and the recently identified FANCI remains to be determined. FANCI plays a pivotal role in the pathway (4, 5) and there is mounting evidence and novel mechanistic insights toward FANCL being the ubiquitin ligase (E3) enzyme within the FA core complex (18, 19) . Importantly, it has been recently proposed a direct participation of FANCM in the DNA repair process (20, 21) . Functional relevance of the three proteins and lack of information with regards to their potential implication in breast cancer predisposition prompted us to analyze the entire coding sequence and splicing sites of FANCI, FANCL and FANCM in 95 BRCA1/2-negative Spanish high-risk breast cancer families. With the present study, all known FA genes have been evaluated within the context of breast cancer high-risk predisposition.
Materials and methods

Patients and controls
Index cases from 95 BRCA1/BRCA2 mutation-negative Spanish breast and ovarian cancer families were screened for mutations within the entire coding sequence and splicing sites of FANCI, FANCL and FANCM genes. Families were ascertained in different Spanish hospitals and were selected for mutation analysis if they contained (i) at least three cases of breast or ovarian cancer in the same family line; (ii) at least two first-degree relatives diagnosed with breast cancer before age 50; (iii) at least one case of breast cancer and one case of ovarian or bilateral breast cancer in the same family line; (iv) at least one case of breast and ovarian cancer or (v) at least one case of male breast cancer. Eleven of the 95 families consisted of affected siblings only (only one generation involved) and were distributed as follows: (i) three breast canceraffected sisters, one of them diagnosed before age 50 (n 5 1); (ii) sister pairs, both sisters being affected by breast cancer and diagnosed before 50 (n 5 4), at least one of them affected by ovarian cancer (n 5 2) or at least one of them exhibiting bilateral breast cancer (n 5 3) and (iii) one female and one male breast cancer cases (n 5 1). Controls consisted of 800 healthy individuals Abbreviations: FA, Fanconi Anemia; PCR, polymerase chain reaction.
representative of the Spanish population, mainly recruited from the Menopause Research Centre at the Instituto Palacios (Madrid, Spain) and from the College of Lawyers (Madrid, Spain). Details of this control series have been previously published (22) . The necessary ethics committee approval was obtained as well as informed consent from all participants in the study.
Analysis of BRCA1 and BRCA2
All index cases had been previously screened for mutations in the BRCA1/2 genes by denaturing high-performance liquid chromatography and/or other comprehensive approaches described in detail elsewhere (23) (24) (25) (26) (27) ) and found to be negative.
Mutation analysis of FANCI, FANCL and FANCM genes DNA obtained from peripheral blood of index cases was subjected to wholegenome amplification by using the GenomiPhi V2 Amplification Kit (GE Healthcare UK Limited, Buckinghamshire, UK) according to the manufacturers' instructions. Amplified DNA was then used as template for polymerase chain reaction (PCR) generation of fragments covering FANCI, FANCL and FANCM exons and splicing sites. In order to ensure optimal PCR performance from whole-genome amplified DNA, primers were designed to generate amplicons of size up to 400 bp. The 38 exons of FANCI, 14 exons of FANCL and 23 exons of FANCM were covered with 41, 17 and 37 PCR fragments, respectively. All primer pairs are detailed in supplementary Table I (available at Carcinogenesis Online). PCR products were analyzed by denaturing highperformance liquid chromatography on the WAVE HT system (Transgenomic, Omaha, NE) using an acetonitrile gradient. Navigator TM Software (Transgenomic) was used to look for aberrant denaturing high-performance liquid chromatography patterns suggestive of sequence changes that were further confirmed by bidirectional sequencing using the BigDyeTerminator Cycle sequencing kit and a 3730 automated sequencer (Applied Biosystems, Foster City, CA). All non-described variants/mutations were confirmed by resequencing a fresh aliquot of the non-whole-genome amplification stock DNA.
GenBank Reference sequences used for naming sequence variants were NM_001113378.1 and NP_001106849.1 for FANCI, NM_018062.3 and NP_060532.2 for FANCL and NM_020937.2 and NP_065988.1 for FANCM. Standardized nomenclature was reported considering the A of the ATG initiation codon of the coding DNA Reference Sequence as nucleotide position þ1 (28, 29) .
In silico analysis
To identify potential functional effects of novel missense variants found in our screening, we performed computational analysis by using SIFT (http://sift. jcvi.org/) (30, 31) and PolyPhen (http://coot.embl.de/PolyPhen/) (32,33) softwares. Both programs are web-based automatic tools for predicting possible impact of amino acid substitution on the structure and function of proteins. We were also interested in predicting possible effects on splicing of intronic variants and for that purpose we used the Alamut software (Interactive Biosofware, Rouen, France) that performs splicing predictions based on three different algorithms, Splice-Site Finder (http://www.umd.be/HSF/), MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) (34) and Gene Splicer (http://www.cbcb.umd.edu/software/GeneSplicer/) (35) .
Results
FANCI mutation analysis
Given the recent identification of FANCI, the gene responsible for the FA-I complementation group, we prioritized mutational screening of this locus. DNAs from 95 index patients from high-risk breast cancer families negative for mutations in the BRCA1 and BRCA2 genes were scrutinized for sequence variants. We examined FANCI whole-coding sequence and splicing sites and found 29 sequence variants, 20 of them were non-coding and 9 coding (Table I) . Eleven of the noncoding variants had not been described previously as well as one non-synonymous coding change (c.2146A.G; p.S716G) ( Table I) . In silico analysis of the non-synonymous coding variant indicated a possible pathogenic role (using Polyphen software) and we proceed to analyze 68 more cases and nearly 800 control individuals. One individual from our control population showed the variant (1/792; 0.12%) but no more carriers were detected among the additional cases. We also looked for possible effects on splicing caused by the 11 novel intronic variants but computational analysis indicated unlikely that major changes in splicing might occur due to the sequence changes.
FANCL mutational analysis
Screening of all 14 exons and intron-exon boundaries of FANCL revealed 14 sequence variants, 2 of them coding and 12 non-coding (Table II) . Among the non-coding variants, eight were novel but none of them involved consensus splicing sites and in silico analysis did not predict new or broken splicing sites neither major alterations on branch sites.
FANCM mutational analysis FANCM, the largest gene of the three analyzed in this study with a coding sequence .7000 bps (23 exons) and 2048 amino acids, was covered with 37 PCR fragments. We detected a total number of 25 sequence variants, 13 coding and 12 non-coding (Table III) . Among the exonic variants, five had not been described previously and three of them produced an amino acid substitution. To identify potential functional effects of the missense variants, we performed in silico analysis. The novel non-synonymous variant c.5569G.A, p.V1857M was predicted to affect protein function by SIFT. In view of its potential functional impact, we screened this sequence change in our control population finding two carriers of 800 individuals (0.2%).
As for the non-described non-coding variants, none of the three programs used rendered high enough scores as to predict major changes in splicing.
Discussion
The majority of breast cancers are sporadic but $20% of these neoplasms present some type of familial aggregation or a clear hereditary pattern. BRCA1 and BRCA2 are the most important high-penetrance genes associated with breast and ovarian cancer susceptibility but we currently know that mutations in these two genes only explain up to 25% of the high-risk families (24, 36) . Rare mutations in other highrisk genes such as P53, PTEN or STK11 also account for a small percentage of inherited breast cancer within specific cancer-prone syndromes (37) (38) (39) . Other genes known to confer a moderate breast cancer risk ($2-to 4-fold) are ATM, CHEK2, RAD50, NBS1 or the recently reported FANCN/PALB2 or FANCJ/BRIP1 (10, 11, (40) (41) (42) . Altogether, we can say that ,30% of familial breast cancer risk can be explained by mutations in known genes, which makes the search for new susceptibility candidate genes a priority within the field of breast cancer research.
Importantly, all known breast cancer genes are involved in the maintenance of genomic stability and therefore, it is reasonable to regard genes engaged in preservation of the genome integrity as good candidates for breast cancer predisposition. Remarkably, three of the known breast cancer susceptibility genes are FA genes. Homozygous mutations in the FANCD1/BRCA2, FANCN/PALB2 and FANCJ/ BRIP1 genes result in FA phenotype while heterozygous mutations at these loci predispose to breast cancer. This makes all FA genes particularly attractive candidates. Most other FA genes have currently been screened for mutations in high-risk breast cancer families negative for BRCA1/2 mutations and consequently ruled out as major susceptibility breast cancer risk (9, 12) . However, similar analyses have not yet been reported for FANCI, FANCL and FANCM, which prompted us to scrutinize all coding sequences and splicing sites of the three genes in 95 BRCA1/2-negative index cases from Spanish high-risk breast cancer families. Importantly, novel data sustaining greater functional relevance of the three genes within the pathway further support the interest of our current screening.
FANCI, the most recently identified FA proteins, is an ATM/ATR kinase substrate that associates with its paralogue FANCD2 to constitute what it has been termed 'ID complex' (3) (4) (5) . Upon DNA damage, monoubiquitination of both proteins by the FA 'core complex' targets the ID complex to DNA damage sites in chromatin (nuclear foci) where it would participate in DNA damage recognition and repair (6) . Importance of FANCI function within the pathway has been further reinforced by a new study showing that ATR-mediated FANCI phosphorylation is the key event that triggers monoubiquitination of its partner FANCD2, which is essential for FA pathway function M.J.García et al. (43, 44) . Upon examination of all coding regions and splicing sites of FANCI, we identified 29 sequence variants, 12 of them not described previously. Among these, 11 were intronic and did not involve consensus splice sites; therefore, we considered unlikely a possible pathogenic effect of any of them. The remaining non-described variant corresponded to the non-synonymous coding change c.2146A.G, p.S716G that was predicted as possibly damaging. A frequency of the variant of 0.12% in our control population does not allow drawing more definitive conclusion regarding its pathogenic effect. We could not carry out segregation analysis but further studies will be performed in order to fully determine the functional role of this sequence change. In view of our results, we may rule out a major contribution of FANCI as a high-penetrance breast cancer susceptibility gene.
As it happens for FANCI, recent reports indicate a fundamental role for FANCL in the crucial FANCD2 monoubiquitination step. Although suspected for a long time, it has not been proved until now by in vitro assays that FANCL is indeed the putative E3 ubiquitin ligase subunit within the FA core complex (18) . Furthermore, it has also been shown that FANCL not only recruits Ube2t, the relevant E2 ubiquitin-conjugating enzyme in the process, but also enhances the efficiency of FANCD2 monoubiquitination by stimulating Ub2t activity. Despite this clear interest as possible candidate gene, results from our mutational screening of FANCL did not reveal any pathogenic change. All seven detected non-described variants corresponded to intronic changes and none of them seemed to affect consensus splicing sites. Therefore, it does not seem probably that this gene might have a major role as high-risk breast cancer gene.
Of the three genes we have analyzed in the current study, FANCM presents certain features that might suggest a more promising role as possible breast cancer susceptibility gene. FANCM forms part of the FA core complex and it is the only of the eight FANC core complex proteins that presents DNA-interacting and enzymatic activities through its helicase domain (6, 45) . It was initially suggested that FANCM would participle in translocation of the FA core complex to the damage sites allowing ubiquitination step (45) but in addition to that role, there are now new pieces of evidence that suggest a direct participation of FANCM in DNA repair process (20, 21, 46) . This would potentially make FANCM more likely to be a breast cancer susceptibility gene since the three FA genes known to confer increased breast cancer risk function downstream FANCD2 ubiquitination. However, after thorough scrutiny of FANCM coding sequence (.7000 bp), we could not detect any clearly pathogenic change. Similarly, examination of intron-exon boundaries did not reveal any variants potentially leading to aberrant splicing and ultimately to nonfunctional protein. Novel non-synonymous sequence variant c.5569G.A, p.V1857M was predicted to affect protein activity. Low frequency in our control population (0.2%) and lack or segregation data guarantee future functional assays to fully elucidate implication of this sequence change in the protein activity.
With the present study, all known FA genes have been evaluated within the context of breast cancer high-risk predisposition, this analysis being the first reporting a mutational screening of the FA genes FANCI, FANCL and FANCI. Analysis of 95 BRCA1/2-negative highrisk breast cancer families lead to the identification of a total of 68 sequence variants of which 32 were novel, 6 of them coding and 26 non-coding. None of the novel sequence changes presented a clear pathogenic effect. Our results would rule out a major contribution of FANCI, FANCL and FANCM to familial breast cancer susceptibility, suggesting that among the 13 known FA genes, only FANCD1/BRCA2 plays an important role in high-risk breast cancer predisposition. However, this study was conducted in Spanish population and the fact that it is not clear how translatable our results would be within other 
